The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients.

This study tests a combination of two drugs — thiotepa and pomalidomide — for people with primary central nervous system lymphoma (a cancer that starts in the brain or spinal cord) that has come back or stopped responding to prior treatment. **You may be eligible if...** - You are between 18 and 75 years old with confirmed primary CNS lymphoma - Your cancer has returned or progressed after at least one prior chemotherapy course - You have measurable disease on brain MRI or abnormal cerebrospinal fluid - Your organ function meets the required levels - Your expected survival is more than 3 months **You may NOT be eligible if...** - You are pregnant or breastfeeding - Your lymphoma has spread outside the brain or spinal cord - You have severe bone marrow failure (very low blood counts) - You have HIV, active hepatitis, or another uncontrolled infection - You have had an organ or stem cell transplant from a donor - You have a history of significant psychiatric or neurological disorders Talk to your doctor to see if this trial is right for you.